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Expression of gag/pol and env genes of human immunodeficiency virus requires the viral Rev protein. Mutant Rev proteins,
displaying a transdominant phenotype (TDRev), were shown to inhibit Rev function. To investigate the underlying mechanism
of this inhibition, the green fluorescent protein (GFP) of Aequorea victoria was fused to Rev and TDRev, which allowed the
study of their trafficking and interactions in living human cells. Both Rev-GFP and TDRev-GFP were shown to retain appro-
priate nucleolar localization and function. Upon actinomycin D treatment, Rev-GFP was transported to the cytoplasm within
1.5 hr, while TDRev, although partially dissociated from the nucleolus, was retained in the nucleus. Coexpression of Rev-
GFP and TDRev in the same cell demonstrated that TDRev inhibited the transport of Rev-GFP from the nucleus to the
cytoplasm. This inhibition was specific for Rev, since the export of the functionally analogous Rex protein of the human T-
cell leukemia virus type I was not inhibited by TDRev. These results indicate that Rev and TDRev form heteromultimers in
the nucleolus and that this interaction prevents Rev’s export from the nucleus to the cytoplasm. In addition to providing a
model for the function of TDRev, these results also demonstrate the successful application of protein fusions to GFP to
study localization and trafficking of proteins in living mammalian cells. q 1995 Academic Press, Inc.
INTRODUCTION Bartel et al., 1991; Cook et al., 1991) identified in the env
coding region of HIV-1 (Dayton et al., 1988; Rosen et al.,
The Rev protein is an essential viral factor for HIV-1
1988; Emerman et al., 1989; Felber et al., 1989b; Hadzo-
replication (Feinberg et al., 1986; Sodroski et al., 1986).
poulou-Cladaras et al., 1989; Hammarskjo¨ld et al., 1989;
Rev promotes the transport, stability, and translation of
Malim et al., 1989c; Cochrane et al., 1990a). This type of
unspliced and partially spliced HIV-1 mRNAs responsible
posttranscriptional control is most conserved among all
for the production of the viral structural proteins (Chang lentiviruses and in the HTLV family of primate oncovi-
and Sharp, 1989; Emerman et al., 1989; Felber et al.,
ruses, which encode a similar protein named Rex (Kiyo-
1989b; Hammarskjo¨ld et al., 1989; Malim et al., 1989c;
kawa et al., 1985; Inoue et al., 1986, 1987; Nagashima et
Lu et al., 1990; Arrigo and Chen, 1991; Lawrence et al.,
al., 1986; Derse, 1988; Hidaka et al., 1988; Seiki et al.,
1991; D’Agostino et al., 1992; Schwartz et al., 1992; Nasi-
1988; Dokhelar et al., 1989; Felber et al., 1989a). Exten-
oulas et al., 1994). Rev controls the expression of several
sive cross-reactivity among Rev/Rex and RREs from dif-
HIV-1 proteins at the posttranscriptional level and is not
ferent viruses suggests that they have the same function
required for any other function in cultured cells. This
and in many cases can replace each other (see for exam-
was demonstrated by the construction of infectious HIV-
ple Rimsky et al., 1988; Felber et al., 1989a; Hanly et al.,
1 mutants that do not express Rev but contain other
1989; Itoh et al., 1989; Malim et al., 1989a; Lewis et al.,
posttranscriptional control elements (Bray et al., 1994;
1990; Tiley et al., 1990; Kim et al., 1991).
Zolotukhin et al., 1994). The dramatic effects of Rev on
Rev accumulates in the nucleolus (Cullen et al., 1988;
the posttranscriptional control of gene expression are Felber et al., 1989b; Cochrane et al., 1990b) and shuttles
mediated by the binding of Rev to a unique RNA element
between the nucleolus and the cytoplasm (Kalland et
termed the Rev-responsive element or RRE (Daly et al.,
al., 1994a; Meyer and Malim, 1994; Richard et al., 1994;
1989; Heaphy et al., 1990; Holland et al., 1990, 1992;
D’Agostino et al., 1995). Two functionally important re-
gions have been defined in the 116-amino-acid Rev pro-
tein (for reviews see Cullen, 1991; Parslow, 1993). The N-1 The U.S. Government’s right to retain a nonexclusive royalty-free
license in and to the copyright covering this paper, for governmental terminal region, approximately residues 14 – 60, contains
purposes, is acknowledged. the specific RRE binding domain, the arginine-rich nu-2 To whom correspondence and reprint requests should be ad-
clear/nucleolar localization signal, and regions that aredressed at: ABL-Basic Research Program, Bldg. 539, Rm. 121, NCI-
important for oligomerization (Malim et al., 1989b; Per-FCRDC, P.O. Box B, Frederick, MD 21702-1201. Fax: (301) 846-5991.
E-mail: pavlakis@ncifcrf.gov. kins et al., 1989; Hope et al., 1990a; Olsen et al., 1990;
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Bo¨hnlein et al., 1991; Zapp et al., 1991). The C-terminal transfection, the cells were supplemented with 25 mg/ml
of cycloheximide (Sigma) for 30 min, followed by additionleucine-rich effector domain spans approximately resi-
dues 78 – 90. Mutations in the Rev effector domain cause of 2 mg/ml of actinomycin D (Sigma). After addition of the
drugs, cells were further incubated for 1.5 hr and visuallya dominant negative phenotype (Malim et al., 1989b;
Hope et al., 1990a; Mermer et al., 1990; Venkatesh and inspected by confocal laser scan microscopy or fixed for
immunofluorescence studies. In experiments using 293Chinnadurai, 1990; Malim et al., 1991), while mutations
in the N-terminal region yield recessive negative Rev cells, Tat protein was provided by cotransfection with the
Tat expression plasmid pL3tat (Felber et al., 1990).proteins. The dominant negative Rev protein M10 is able
to suppress viral replication when expressed in stable
Protein analysiscell lines (Bevec et al., 1992; Malim et al., 1992; Bahner
et al., 1993; Escaich et al., 1995). Human 293 cells were transfected with the indicated
Despite extensive study, the molecular mechanism of plasmids. The cells were harvested in 300 ml 0.5 RIPA
transdominance and important questions related to Rev buffer [50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-
colocalization and interactions with other cellular compo- 100, 1% sodium deoxycholate, 0.1% SDS (Hadzopoulou-
nents remain unanswered. To address these questions, Cladaras et al., 1989)]. After lysing the cells by three
we constructed fusions of Rev and a TDRev mutant to the cycles of freeze-thawing the lysates were clarified by
green fluorescent protein (GFP) isolated from Aequorea centrifugation. The clarified protein extracts were subse-
victoria (Prasher et al., 1992). This protein contains a quently analyzed by sodium dodecyl sulfate (SDS) – poly-
tripeptide fluorophore produced by posttranslational, acrylamide gel electrophoresis (PAGE) and Western im-
nonenzymatic modification of the protein that emits green munoblotting. Blots were incubated with a 1:200 dilution
light when excited with UV light (Heim et al., 1994). In of rabbit anti-Rev polyclonal antiserum in phosphate-buf-
this report, we show that fusion to GFP does not affect fered saline (PBS) (D’Agostino et al., 1995), followed by
the biological activities of the HIV-1 Rev and TDRev pro- 125I-labeled protein A (Amersham).
teins. This approach allowed us to use the fusion pro-
teins to examine the trafficking of Rev and TDRev pro- Indirect immunofluorescence analysis of proteins
teins in living human cells by confocal laser scan transiently expressed in HLtat cells
microscopy. Our results suggest that TDRev forms het-
HLtat cells were transfected with the indicated plas-eromultimers with Rev that are retained in the nucleus.
mids. Twenty-four hours later, the cells were supple-This finding provides a model for the mechanism of
mented with 25 mg/ml of cycloheximide for 30 min, fol-TDRev function.
lowed by addition of 2 mg/ml of actinomycin D for 1.5 hr.
The cultures were then rinsed twice with PBS, fixed withMATERIALS AND METHODS
3.7% formaldehyde in PBS for 20 min, washed three times
Cells and transfections with PBS, and permeabilized in 0.1% NP-40 for 10 min.
Following three PBS washes, the cells were incubatedFor fluorescence, immunocytochemistry, and micro-
for 1 hr at 377 with a rabbit anti-Rev polyclonal antiserumscopic studies, we used the HLtat cell line (Schwartz
(D’Agostino et al., 1995) or a rabbit anti-Rex polyclonalet al., 1990), a HeLa-derived cell line that constitutively
antiserum (Derse, unpublished data) that had been di-produces the HIV-1 Tat protein. 293 cells, an adenovirus-
luted 1:100 in PBS. After washing the cells extensivelytransformed human embryonal kidney cell line (Graham
with PBS they were incubated for 1 hr with a 1:50 dilutionet al., 1977), were used for protein expression analysis.
of fluorescein isothiocyanate-conjugated goat anti-rabbitCells were cultured in Dulbecco’s modified culture me-
immunoglobulin (Kirkegaard & Perry, Inc.). Followingdium supplemented with 10% heat-inactivated fetal bo-
three additional washing steps with PBS, the cells werevine serum (Biofluids) and transfected in 60-mm dishes
mounted in 90% glycerol (pH 8.0) and examined with a(Falcon) by the calcium phosphate coprecipitation tech-
Zeiss IM35 fluorescence microscope.nique as previously described (Graham and Van der Eb,
1973; Felber et al., 1990). Plasmid DNA was purified by
Microscopy of living cells
Qiagen columns according to the manufacturer’s instruc-
tions (Qiagen). The transfection mixture for each 60-mm HLtat cells were seeded into Lab-Tek chambered
cover glass (Nunc) and transfected after 24 hr with theplate contained 1 mg of the indicated plasmids and was
adjusted to 17 mg with pBluescript DNA (Stratagene). indicated plasmids. Twenty-four hours later, the cells
were treated with 25 mg/ml of cycloheximide for 30 minThe cells were harvested 2 days after transfection and
cytoplasmic extracts were prepared as described pre- followed by 2 mg/ml of actinomycin D as indicated. The
cultures were further incubated for 1.5 hr at 377 andviously (D’Agostino et al., 1992). The production of HIV-
1 Gag protein was measured by a p24gag antigen capture analyzed by a Zeiss LSM 410 Micro System in the confo-
cal mode. For GFP excitation, the argon laser at 488-nmassay (Cellular Products) according to the manufacturer’s
instructions. For protein trafficking studies, at 24 hr post- wavelength was used.
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Recombinant plasmids RESULTS
Rev-GFP and TDRev-GFP fusion proteins arepBSPL is a modified pBluescript (KS0) vector used as
efficiently expressed in human cellsDNA carrier in our transfection experiments. pBsrev is a
derivative of pLsrev (Mermer et al., 1990; D’Agostino et To study the trafficking of the HIV-1 Rev protein in
al., 1995). pBsrevM10BL produces the TDRev mutant living cells, the GFP was fused to the C-terminus of both
RevM10BL. This mutant contains the M10 mutations Rev and the transdominant Rev (TDRev) mutant
(Malim et al., 1989b), Asp78 to Leu and Leu79 to Glu, RevM10BL (Fig. 1). The Rev-GFP fusion protein contains
and the BL mutations (Mermer et al., 1990), an insertion amino acids 1 –111 of Rev, followed by a four-amino-acid
(Glu-Asp-Leu-Pro) between amino acids 81 and 82 (Song linker (Asp-Ala-Gln-Glu) and the complete GFP protein.
et al., manuscript in preparation). Plasmid pB37R con- Therefore, Rev-GFP lacks six C-terminal residues of Rev
tains the HIV-1 5* LTR promoter, p37gag coding region, that have been shown to be dispensable for function
RRE330, and HIV-1 3* LTR (Tabernero et al., 1995). This (Cochrane et al., 1989; Mermer et al., 1990). TDRev con-
construct expresses gag in a Rev-dependent manner. To tains a combination of two previously characterized
generate plasmid pCMV-GFP, the GFP coding sequence transdominant mutations M10 (Malim et al., 1989b) and
from plasmid TU58 (Chalfie et al., 1994) was amplified RevBL (Mermer et al., 1990), consisting of two amino acid
by the polymerase chain reaction (PCR). The PCR product changes (M10) and an insertion of four amino acids (BL)
was digested with BssHII and BamHI and cloned into in the effector domain (Song et al., manuscript in prepara-
the pCMV37M1-10D vector, replacing the gag gene. tion). TDRev-GFP is identical to Rev-GFP, except in the
pCMV37M1-10D contains the cytomegalovirus early pro- region of the effector domain.
moter and the HIV-1 p37gag coding region, followed by To examine the expression of the proteins synthesized
several cloning sites and the HIV 3* LTR (Schneider and from the hybrid genes, human 293 cells were transfected
Pavlakis, unpublished data). For the PCR amplification, with the Rev-GFP or TDRev-GFP plasmids in the pres-
the oligonucleotide 16417 (5* GGAGGCGCGCAAGAA- ence of the Tat-producing plasmid pL3tat to induce the
ATGGCTAGCAAAGGAGAAGA 3*), containing a BssHII HIV-1 promoter. Equal aliquots of cell lysates were ana-
site and the translation initiation elements of the HIV-1 lyzed by Western immunoblot using a Rev-specific poly-
Tat protein, was used as the sense primer. The antisense clonal antiserum (D’Agostino et al., 1995). As shown in
primer, oligonucleotide 16418 (5* GCGGGATCCTTATTT- Fig. 2, a fusion protein of the expected size was produced
GTATAGTTCATCCATGCCATG 3*), contains a BamHI in substantial amounts from each plasmid. TDRev (lane
site. pBsrev-GFP was constructed by inserting the GFP 4) migrated slightly slower than Rev (lane 6) due to the
coding region into pBsrev. For this purpose the GFP gene mutations in the effector domain (Mermer et al., 1990).
was excised from pCMV-GFP using restriction enzymes TDRev-GFP also showed the altered electrophoretic mo-
BssHII and BamHI and inserted by blunt-end ligation into bility of the TDRev. No bands were detected in lysates
the XhoI site of pBsrev. This cloning procedure generated from untransfected cells (lane 2) or cells transfected with
a Rev-GFP fusion protein consisting of the Rev residues pBSPL vector DNA only (lane 1), thereby demonstrating
1– 111 (lacking the six C-terminal amino acids), followed the specificity of the immunostaining. These results dem-
by a short peptide linker (Asp-Ala-Gln-Glu) and the com- onstrated that the GFP portion did not affect the accumu-
plete GFP protein. pBsrevM10BL-GFP was produced by lation of the fusion proteins.
inserting the GFP-containing fragment from pBsrev-GFP
into pBsrevM10BL. The expressed RevM10BL-GFP fu- Fusion to GFP does not affect the biological function
sion protein is identical to the Rev-GFP with the excep- of Rev and transdominant Rev
tion of the M10 and BL mutations described for
We next tested the biological activity of the GFP fusionRevM10BL. pL3Rex, which produces the HTLV-I regula-
proteins in a functional assay. We measured the Rev-de-tory protein Rex, has been described previously (Solomin
pendent expression of HIV-1 gag from the subgenomicet al., 1990).
expression vector pB37R (Tabernero et al., 1995). This vec-
tor contains the coding region of HIV-1 p37gag and the RRE.
DNA sequence analysis 293 cells were transfected with pB37R in the presence or
absence of the rev expression vectors (pBsrev, pBsrev-
DNA sequencing was performed by the PCR-assisted GFP) alone or in combination with the TDRev-producing
fluorescent terminator method (ReadyReaction Dye- plasmids (pBsrevM10BL, pBsrevM10BL-GFP). Two days
Deoxy Terminator Cycle Sequencing Kit, ABI) according later, the cells were harvested and Gag production was
to the manufacturer’s instructions, and reactions were quantitated by a commercially available p24gag antigen cap-
resolved on the ABI Model 373A DNA Sequencing Sys- ture assay (Fig. 3). The presence of either Rev or Rev-GFP
tem. Sequencing data were analyzed using the stimulated the expression of Gag protein approximately
100-fold. As expected, the effector domain mutantSequencher program (Gene Codes).
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FIG. 1. Schematic representation of the plasmids expressing Rev, TDRev, and GFP fusion proteins. The constructs contain part of the HIV-1 5*
LTR (U3 and part of the R region, up to nucleotide /80) and the polyadenylation signal (poly(A)) of SV40. pBsrev encodes the complete Rev protein;
pBsrevM10BL encodes the 121-amino-acid TDRev protein (RevM10BL). The amino acid changes between Rev and TDRev are indicated in boldface
letters. pBsrev-GFP encodes a fusion protein of 359 amino acids; pBsrevM10BL-GFP encodes a fusion protein of 363 amino acids. The GFP coding
region is indicated by a shaded bar.
RevM10BL and RevM10BL-GFP fusion proteins were both or absence of actinomycin D, a drug that affects nucleolar
inactive. The transdominant phenotype was demonstrated function. We also treated the transfected cells with cyclo-
by coexpression of Rev and TDRev or Rev-GFP and TDRev- heximide 30 min prior to actinomycin D addition, to block
GFP at a molar ratio of 1:1, which resulted in a 5-fold new protein synthesis. However, under our experimental
reduction of Gag production. These results indicate that conditions, omission of cycloheximide did not alter the
both hybrid proteins are functional. results (data not shown). Using actinomycin D, several
groups have demonstrated that Rev is capable of shut-
Transdominant RevM10BL prevents the shuttling of tling between the nucleus and the cytoplasm (Kalland et
Rev-GFP from the nucleus to the cytoplasm al., 1994a; Meyer and Malim, 1994; Richard et al., 1994;
D’Agostino et al., 1995).We examined the localization and trafficking of the
To study localization and trafficking of the GFP-taggedRev-GFP fusion proteins in living cells in the presence
proteins, HLtat cells were transfected with the different
expression vectors and inspected without fixation by con-
focal laser scan microscopy. HLtat cells are well
attached to the tissue culture plates and have a flat mor-
phology, which facilitates morphological studies. Expres-
sion and localization of GFP hybrid proteins were similar
in both HLtat and 293 cells, as well as in several other
human cell lines tested (data not shown). As shown in
Fig. 4, GFP protein alone is equally distributed throughout
the cell except for the nucleoli, and actinomycin D treat-
ment did not affect its localization. However, both Rev-
GFP and TDRev-GFP were detected only in the nucleolus
in the absence of actinomycin D. In contrast to a report
by Kalland et al. (1994b), we did not observe any Rev
localized in nucleoplasmic speckles. After actinomycin
FIG. 2. Detection of wild-type Rev, Rev-GFP, RevM10BL, and D treatment, Rev-GFP was almost completely transported
RevM10BL-GFP proteins after transient transfections. 293 cells were to the cytoplasm within 1.5 hr, while TDRev-GFP, al-
transfected with 1 mg of the expression plasmids together with 1 mg
though partially dissociated from the nucleolus, was re-of pL3tat per 60-mm dish and harvested 2 days later. Proteins were
tained in the nucleus. Substantial movement of Rev-GFPseparated on a 12% SDS –PAGE gel and detected by immunoblotting
using a polyclonal antiserum directed against Rev. Lane 1, pBSPL to the cytoplasm could be observed as early as 30 min
control plasmid; lane 2, untransfected 293 cells; lane 3, pBsrevM10BL- after drug treatment (data not shown). Coexpression of
GFP; lane 4, pBsrevM10BL; lane 5, pBsrev-GFP; lane 6, pBsrev. The RRE-containing Rev-dependent gag mRNA did not alterpositions of the 14C-labeled protein standards (lane 7, Amersham) are
the subcellular distribution of Rev-GFP and TDRev-GFPindicated to the left. The radioactive protein bands were too weak to
be detected in this exposure. (data not shown), in agreement with results reported by
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FIG. 3. Fusion to GFP does not affect the function of Rev and TDRev. 239 cells were transfected with 1 mg of each of the indicated plasmids,
together with 1 mg of pL3tat and 2 mg of the gag-expressing plasmid pB37R. Two days later the cells were harvested and Gag production was
measured by a p24gag antigen capture assay. Duplicate 293 plates were used and the results were averaged. Similar results were obtained in three
independent experiments.
other groups (Kalland et al., 1994a; Meyer and Malim, related HTLV-I Rex protein. Rex is also a nuclear/nucleo-
lar protein (Siomi et al., 1988; Nosaka et al., 1989) that1994; Richard et al., 1994).
We next examined the effect of TDRev on Rev-GFP is able to bind to the RRE of HIV-1 (Bogerd et al., 1991;
Unge et al., 1991) and to replace Rev function (Rimskytrafficking upon coexpression of the two proteins within
the same cell (Fig. 4, lower left panel). We observed that, et al., 1988; Felber et al., 1989a; Hanly et al., 1989; Itoh
et al., 1989; Lewis et al., 1990). Indirect immunofluores-although Rev-GFP still localized in the nucleolus in the
presence of TDRev, the staining of the nucleolar region cence studies of HLtat cells transfected with the Rex
expression plasmid pL3Rex demonstrated that the Rexwas more diffuse. Treatment of the transfected cells with
actinomycin D revealed that in the presence of TDRev protein was localized primarily in the nucleolus and nu-
cleus of transfected HLtat cells (Fig. 5A). Upon actinomy-the transport of Rev-GFP from the nucleus to the cyto-
plasm was inhibited (Fig. 4, lower right panel). This inhibi- cin D treatment, Rex was transported efficiently to the
cytoplasm (Fig. 5C). The presence of TDRev did not affecttory effect was not observed when Rev was coexpressed
with the Rev-GFP hybrid (data not shown). Similar results the nuclear/nucleolar localization of Rex (Fig. 5B) or Rex’s
transport to the cytoplasm after drug treatment (Fig. 5D).were also obtained by indirect immunofluorescence
studies using Rev and TDRev, indicating that the inhibi- These data indicate that Rex is also shuttling between
nucleus and cytoplasm. In contrast to the inhibition oftory effect of TDRev on Rev trafficking is not caused by
the GFP component of the Rev-GFP protein (data not Rev trafficking by TDRev (Fig. 4, bottom panel), Rex was
not affected by the same treatment, indicating specificityshown). Furthermore, in additional cotransfection experi-
ments we verified that the levels of Rev-GFP expression of inhibition by TDRev.
were the same in the presence or absence of TDRev,
DISCUSSIONexcluding the possibility of artifacts due to changes in
the expression levels (data not shown). These data dem- The present work demonstrates that fusions of GFP to
onstrate that the interaction of TDRev with Rev-GFP led Rev and TDRev of HIV-1 result in functional proteins that
to inhibition of the transport of Rev-GFP to the cytoplasm. can be studied in living cells. The analysis of Rev local-
ization in living cells confirms previous reports that Rev is
Inhibition of nuclear export by TDRev is specific for
a nucleocytoplasmic shuttle protein (Kalland et al., 1994a;
the Rev protein
Meyer and Malim, 1994; Richard et al., 1994; D’Agostino
et al., 1995) concentrated mainly in the nucleolus (CullenTo further examine whether inhibition of Rev transport
by TDRev was specific or was due to a nonspecific et al., 1988; Felber et al., 1989b; Cochrane et al., 1990b).
Upon actinomycin D treatment, Rev-GFP was transportedblockage of a general nuclear export pathway, we tested
the effect of TDRev on the localization of the functionally from the nucleolus to the cytoplasm in less than 1.5 hr.
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FIG. 5. Rex localization is affected by actinomycin D but not by TDRev. Two parallel sets of HLtat cells were transfected by a rex-expressing
plasmid (pL3Rex) in the absence or presence of the TDRev-producing plasmid (pBsrevM10BL). The next day the cells were fixed and subjected to
immunofluorescence analysis using a rabbit anti-Rex antiserum. One set of plates was treated with actinomycin D for 1.5 hr before fixation. (A)
pL3Rex; (B) pL3Rex plus pBsrevM10BL; (C) pL3Rex, actinomycin D treated; (D) pL3Rex plus pBsrevM10BL, actinomycin D treated.
The transdominant RevM10BL-GFP was also localized in rect immunofluorescence analysis using Rev and TDRev,
excluding potential artifacts caused by the GFP protein.the nucleolus. However, upon actinomycin D treatment
TDRev was not transported in the cytoplasm but was In our studies of living cells, we did not detect any Rev
in nuclear speckles, in contrast to one report (Kalland etfound in both the nucleolus and the nucleus. Failure of
nucleocytoplasmic shuttling has previously been re- al., 1994b). This discrepancy could be due to the cell
type used for the experiments (rev-expressing HeLa cellported for a similar TDRev protein (Meyer and Malim,
1994). Our observations further underline the importance lines or COS cells versus transient transfected HLtat
cells) or the study of methanol-fixed versus living cells.of the leucine-rich effector domain, the proposed interac-
tion site for cellular cofactors necessary for the nuclear Different fixation protocols (e.g., methanol versus para-
formaldehyde) and permeabilization procedures (e.g., sa-export of Rev (Hope et al., 1992; Meyer and Malim, 1994).
In addition to the advantages for localization and trans- ponin versus NP-40) used in indirect immunofluores-
cence studies may also affect Rev localization (Felber etport studies of Rev and TDRev, the tagging of these poly-
peptides with GFP allowed for the first time the examina- al., 1989b; D’Agostino et al., 1995).
Actinomycin D has been shown to promote nucleolartion of their interactions in living human cells. Coexpres-
sion of Rev-GFP and TDRev in the same cell dissociation and cytoplasmic localization of several nu-
cleolar proteins (Borer et al., 1989), pre-mRNA bindingdemonstrated that TDRev inhibited the transport of Rev-
GFP from the nucleus to the cytoplasm in the presence proteins (Pinol-Roma and Dreyfuss, 1992), and Nopp140
(Meier and Blobel, 1992). This inhibitor also affects theof actinomycin D. Similar results were obtained with indi-
FIG. 4. Transdominant RevM10BL inhibits the shuttling of Rev-GFP from the nucleolus to the cytoplasm after treatment with actinomycin D. Two
parallel sets of HLtat cells were transfected with the indicated plasmids. Panels on the left show cells in the absence of actinomycin D, while
panels on the right show cells 1.5 hr after actinomycin D treatment. Both the control and actinomycin D-treated cells were also treated with
cycloheximide.
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nucleolar architecture (Chan, 1992; Yokoyama et al., Rev and TDRev may still be able to form complexes and
bind to RRE in vivo as suggested above, but may fail to1992) and inhibits RNA polymerases I and II at concentra-
tions above 0.04 mg/ml (Perry and Kelley, 1970). An intact interact with the postulated cellular shuttling factors. This
model is in agreement with most of the data concerningnucleolus and continued rRNA synthesis are essential
for retaining Rev in the nucleus (D’Agostino et al., 1995). TDRev proteins (Hope et al., 1992), with some exceptions
(Kubota et al., 1992; Bogerd and Greene, 1993). KubotaSince actinomycin D may have multiple effects on cell
metabolism, we also studied trafficking in the absence et al. (1992) reported that a Rev mutant protein that lacks
residues 38– 44 remained in the cytoplasm and stronglyof this drug. Heterokaryon fusion experiments between
transfected and nontransfected cells showed that, upon inhibited Rev function by interfering with the nuclear/
nucleolar localization of Rev. However, when we testedfusion of cells coexpressing both Rev-GFP and TDRev to
nontransfected cells, a big delay in the export of Rev- a fusion of this mutant Rev protein to GFP, we could
not observe any inhibition of Rev function (Stauber andGFP to the nontransfected fusion partner was observed
(Neumann et al., manuscript in preparation). Pavlakis, unpublished data). Bogerd and Greene (1993)
excluded the possibility of Rev– TDRev heterodimer for-The inhibitory effect of TDRev appears to be specific
for the HIV-1 Rev protein, since the shuttling of the HTLV- mation in vivo, based on analysis of protein– protein inter-
action using a two-hybrid assay system in mammalianI Rex protein was not inhibited by TDRev. Rex is a func-
tional analog of Rev, which can bind to RRE and replace cells. Since a GAL4-TDRev failed to bind to Rev-VP16
efficiently and to promote the formation of functionalRev (Rimsky et al., 1988; Felber et al., 1989a; Hanly et
al., 1989; Itoh et al., 1989; Lewis et al., 1990). Our study Gal4-VP16 complexes in the nuclei of COS cells, these
investigators concluded that Rev and TDRev do not formfurther expands the similarities between these two regu-
latory proteins to their trafficking patterns in the cell. dimers. However, the sensitivity of this assay might not
allow discrimination between no interaction and aSince TDRev did not affect the localization of Rex, we
conclude that the effect of TDRev on Rev localization is weaker interaction, and the possibility of functional
changes or incorrect localization of the fusion proteinsspecific and may be mediated by the direct interaction
of Rev and TDRev. In contrast, Rex and TDRev may not was also not tested. Studies performed by Daly et al.
(1993) demonstrated that C-terminal deletion mutants ofinteract directly to form protein dimers. To date several
investigators have reported that Rev and TDRev are ca- Rev displayed reduced multimerization on the RRE in
vitro, but still possessed biological activity. The possibil-pable of forming heteromultimer complexes because the
N-terminal multimerization domain is present on both ity that TDRev displays a reduced affinity for heterodimer
formation may account for the different conclusions.proteins (Olsen et al., 1990; Hope et al., 1992). The forma-
tion of specific heterodimers explains easily the specific- Protein fusions with GFP are a useful tool for the study
of protein localization and trafficking. Among the possibleity of inhibition by TDRev because Rex and Rev are not
able to form heterodimeric complexes (Bogerd and disadvantages of GFP as a protein tag is its considerable
size (238 amino acids), although the demonstration ofGreene, 1993).
Our study provides evidence that Rev and TDRev pro- functional fusion proteins in mammalian cells (Marshall
et al., 1995; this study) and in Drosophila (Wang andteins interact to form heteromultimers in vivo which are
less suited for nuclear export and therefore inhibit the Hezelrigg, 1994) indicates that this is not a prohibitive
problem. Mutagenesis of GFP showed that very little oftransport of unspliced or incompletely spliced HIV-1
mRNAs. This model would suggest that the binding site the protein can be deleted without affecting its fluores-
cence properties (Gaitanaris et al., unpublished data).for the essential ‘‘cellular shuttling factors’’ may be com-
posed of the leucine-rich effector domain of several inter- Wang and Hezelrigg reported higher sensitivity of direct
GFP detection compared to immunofluorescence in Dro-acting Rev proteins. The fact that even single amino acid
changes between residues 79 and 88 result in Rev pro- sophila embryos. In contrast, the sensitivity of Rev-GFP
detection in human cells in tissue culture is lower thanteins with a transdominant phenotype suggests that this
region is essential for interaction with the proposed cellu- immunofluorescence using our anti-Rev antiserum.
Therefore, at present, GFP may not be the most sensitivelar cofactors. These data support the conclusion that
these mutations result in loss rather than gain of function detection method, especially for weakly expressed
genes. A new generation of GFP mutants with greatly(Malim et al., 1989b). Both Rev (Daly et al., 1989; Heaphy
et al., 1990; Holland et al., 1990, 1992; Bartel et al., 1991; enhanced emission will alleviate this problem and allow
very sensitive detection of this protein (Gaitanaris et al.,Cook et al., 1991) and TDRev (Benko et al., 1990) were
shown to bind RRE efficiently. The possibility that com- manuscript in preparation; Heim et al., 1994).
There are several advantages for the use of the GFP-plexes between Rev and TDRev are no longer able to
bind to the RRE and therefore are titrating out functional tagging system compared to indirect immunofluores-
cence. First, no secondary manipulations are requiredRev was excluded previously by Olsen et al. (1990).
These investigators demonstrated that Rev– TDRev com- for the detection of the tagged protein, since direct exam-
ination using a fluorescence microscope immediately re-plexes are still able to bind to the RRE in vitro. Therefore,
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